1. Home
  2. MLTX vs CCOI Comparison

MLTX vs CCOI Comparison

Compare MLTX & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLTX
  • CCOI
  • Stock Information
  • Founded
  • MLTX 2021
  • CCOI 1999
  • Country
  • MLTX Switzerland
  • CCOI United States
  • Employees
  • MLTX N/A
  • CCOI N/A
  • Industry
  • MLTX Biotechnology: Pharmaceutical Preparations
  • CCOI Telecommunications Equipment
  • Sector
  • MLTX Health Care
  • CCOI Consumer Discretionary
  • Exchange
  • MLTX Nasdaq
  • CCOI Nasdaq
  • Market Cap
  • MLTX 2.8B
  • CCOI 2.4B
  • IPO Year
  • MLTX N/A
  • CCOI N/A
  • Fundamental
  • Price
  • MLTX $52.40
  • CCOI $30.62
  • Analyst Decision
  • MLTX Strong Buy
  • CCOI Buy
  • Analyst Count
  • MLTX 7
  • CCOI 9
  • Target Price
  • MLTX $74.83
  • CCOI $71.78
  • AVG Volume (30 Days)
  • MLTX 497.4K
  • CCOI 1.1M
  • Earning Date
  • MLTX 08-05-2025
  • CCOI 08-07-2025
  • Dividend Yield
  • MLTX N/A
  • CCOI 13.19%
  • EPS Growth
  • MLTX N/A
  • CCOI N/A
  • EPS
  • MLTX N/A
  • CCOI N/A
  • Revenue
  • MLTX N/A
  • CCOI $922,389,000.00
  • Revenue This Year
  • MLTX N/A
  • CCOI $6.83
  • Revenue Next Year
  • MLTX N/A
  • CCOI $7.64
  • P/E Ratio
  • MLTX N/A
  • CCOI N/A
  • Revenue Growth
  • MLTX N/A
  • CCOI N/A
  • 52 Week Low
  • MLTX $31.42
  • CCOI $29.62
  • 52 Week High
  • MLTX $58.26
  • CCOI $86.76
  • Technical
  • Relative Strength Index (RSI)
  • MLTX 54.60
  • CCOI 15.66
  • Support Level
  • MLTX $51.08
  • CCOI $44.25
  • Resistance Level
  • MLTX $53.78
  • CCOI $45.82
  • Average True Range (ATR)
  • MLTX 2.27
  • CCOI 1.97
  • MACD
  • MLTX -0.42
  • CCOI -1.65
  • Stochastic Oscillator
  • MLTX 55.43
  • CCOI 4.84

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

About CCOI Cogent Communications Holdings Inc.

Cogent carries over one fifth of the world's internet traffic over its network and is a broadband provider for businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.

Share on Social Networks: